Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history fo leukopenia a complete blood count should be monitored frequently during the first few months fo therapy and discontinuation fo the drug should be considered at the first sign fo a clinically significant decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history fo leukopenia a complete blood count should be monitored frequently during the first few months fo therapy and discontinuation fo the drug should be considered at the first sign fo a clinically significant decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history of leukopenia a complete blood count sould be monitored frequently during the first few months of therapy and discontinuation of the drug sould be considered at the first sign of a clinically significant decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of herapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Ptients with  history of leukopeni  complete blood count should be monitored frequently during the first few months of therpy nd discontinution of the drug should be considered t the first sign of  cliniclly significnt decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history of leukopenia a complete blood count should be monitored frequently during eht first few months of ehtrapy and discontinuation of eht drug should be considered at eht first sign of a clinically significant decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drrug should be considered at the first sign of a clinically significant decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients twith a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant declicne in white blood cells
Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy and discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells|Patients with a history of leukopenia a complete blood count should be monitored frequently during the first few months of therapy ancd discontinuation of the drug should be considered at the first sign of a clinically significant decline in white blood cells
